Tweet
Autoantibody response to adjuvant and non-adjuvant H1N1 vaccination in SLE
Murray B. Urowitz MD, FRCP(C),
Anoja Anton MD,
Dominique Ibanez MSc,
Dafna D. Gladman MD, FRCPC,?
DOI: 10.1002/acr.20599
Abstract
Objective:
It has been reported that influenza vaccination increases autoantibody production and/or disease activity in a significant proportion of patients with SLE. During the recent H1N1 epidemic, we investigated whether the use of adjuvant and non-adjuvant containing H1N1 vaccine induced increased autoantibody production in patients with SLE.
Methods:
Patients with SLE who received H1N1 vaccination and had a battery of 9 autoantibodies tested before 1 and 3 months after vaccination were included. Antibodies tested included rheumatoid factor (nephelometry), antinuclear antibody (immunofluorescence), anti-DNA (Farr), anti-RNP, anti-SM, anti-Ro, anti-La, anti-Scl70 and anti-Jo1 (ELISA). Patients were evaluated by standard protocol including items necessary to calculate SLEDAI-2K and SDI. Descriptive statistics and McNemar test were performed to evaluate change in antibodies positivity. Multivariate logistic regression was preformed to adjust for repeated measures in the comparisons of autoantibody over visits and vaccine types.
Results:
103 patients (94F, 9M), with mean age at vaccination of 43.9 (?15.2) years, disease duration 14.2 (?11.0) years were included. 51 patients received adjuvant and 52 non-adjuvant vaccines. Antibody testing was performed a mean of 1.9 months prior to the vaccination. First post-vaccination sample was taken a mean of one month and the second a mean of 3.5 months after vaccination. The percent of patients with changes in antibodies following vaccination was not statistically significant for most antibodies. After adjusting for the number of tests performed none of the associations was significant.
Conclusion:
H1N1 vaccination (both adjuvant and non adjuvant) did not increase the levels of autoantibodies in patients with SLE. ? 2011 by the American College of Rheumatology.
Murray B. Urowitz MD, FRCP(C),
Anoja Anton MD,
Dominique Ibanez MSc,
Dafna D. Gladman MD, FRCPC,?
DOI: 10.1002/acr.20599
Abstract
Objective:
It has been reported that influenza vaccination increases autoantibody production and/or disease activity in a significant proportion of patients with SLE. During the recent H1N1 epidemic, we investigated whether the use of adjuvant and non-adjuvant containing H1N1 vaccine induced increased autoantibody production in patients with SLE.
Methods:
Patients with SLE who received H1N1 vaccination and had a battery of 9 autoantibodies tested before 1 and 3 months after vaccination were included. Antibodies tested included rheumatoid factor (nephelometry), antinuclear antibody (immunofluorescence), anti-DNA (Farr), anti-RNP, anti-SM, anti-Ro, anti-La, anti-Scl70 and anti-Jo1 (ELISA). Patients were evaluated by standard protocol including items necessary to calculate SLEDAI-2K and SDI. Descriptive statistics and McNemar test were performed to evaluate change in antibodies positivity. Multivariate logistic regression was preformed to adjust for repeated measures in the comparisons of autoantibody over visits and vaccine types.
Results:
103 patients (94F, 9M), with mean age at vaccination of 43.9 (?15.2) years, disease duration 14.2 (?11.0) years were included. 51 patients received adjuvant and 52 non-adjuvant vaccines. Antibody testing was performed a mean of 1.9 months prior to the vaccination. First post-vaccination sample was taken a mean of one month and the second a mean of 3.5 months after vaccination. The percent of patients with changes in antibodies following vaccination was not statistically significant for most antibodies. After adjusting for the number of tests performed none of the associations was significant.
Conclusion:
H1N1 vaccination (both adjuvant and non adjuvant) did not increase the levels of autoantibodies in patients with SLE. ? 2011 by the American College of Rheumatology.
